Viyash Scientific Q1 FY27 Revenues Up 19.5% to ₹946.4 Crore, PAT Soars 114.9%
Viyash Scientific reported Q1 FY27 results with revenues at ₹946.4 crore (up 19.5%) and PAT at ₹79.3 crore (up 114.9%). EBITDA grew 59.2% to ₹204.7 crore. The company highlighted the acquisition of Bio For Life in Italy as a strategic step. An earnings call is scheduled for August 12, 2026.
The substantial increase in financial metrics like revenue, EBITDA, and PAT, coupled with a positive management outlook and strategic acquisition details, is expected to have a high impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenues, EBITDA, and PAT, along with a strong commentary from the management about successful integration and strategic acquisitions.
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced its financial results for the quarter ended June 30, 2026, reporting robust growth across key metrics.
Consolidated revenues for Q1 FY27 reached ₹9,464 million (₹946.4 crore), an increase of 19.5% compared to ₹7,916 million (₹791.6 crore) in Q1 FY26. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), excluding ESOP costs, surged by 59.2% to ₹2,047 million (₹204.7 crore) from ₹1,286 million (₹128.6 crore) in the prior year's quarter. The company's Profit After Tax (PAT) demonstrated significant growth, rising by 114.9% to ₹793 million (₹79.3 crore) in Q1 FY27, up from ₹369 million (₹36.9 crore) in Q1 FY26. The Net Debt to EBITDA ratio stood at a healthy 0.1x.
Dr. Hari Babu Bodepudi, Managing Director and Group CEO, commented on the performance, stating, "Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth."
The company will host an earnings call at 3:30 PM IST on August 12, 2026, to discuss its performance and answer investor queries.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.